en · de · es · pt
methods-notes.peptides4800.com › Faq › Tb-500 Identity And Molecular Background — Common Mistakes

Tb-500 Identity And Molecular Background — Common Mistakes

By Editorial Desk · published 2025-07-26 · last reviewed 2025-09-05 · Faq

If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-09-05. Numbers and descriptions here follow the published literature rather than marketing material.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Calculated for the acetylated heptapeptide
Molecular weight~889 DaMonoisotopic mass approximately 889.0 Da
Amino acid sequenceAc-LKKTETQN-terminal acetylated seven-residue peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilized solid
Solubility classWater-solublePeptides of this size generally dissolve in aqueous media

TB-500 Background and Identity

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

Related pages on this site

Thymosin Beta-4 Fragment Identity

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Handling Storage And Analysis

Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.

The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.

Further detail

=== Electronic cross-matching === Electronic cross-matching is a computer-assisted analysis using data, from the donor unit (where a donor's blood is tested prior to donation) and testing done on blood samples from the intended recipient. This includes ABO/Rh typing of the unit and of the recipient, and an antibody screen of the recipient. Electronic cross-matching can only be used if a patient has a negative antibody screen, which means that they do not have any active red blood cell atypical antibodies, or they are below the detectable level of current testing methods. If all of the data entered is compatible, the computer will print a compatibility label stating that the unit is safe to transfuse.

=== Sample introduction and ionization === The first stage of the instrument is an ion source where samples are converted to gas phase ions. Many ionization methods similar to those traditionally used for mass spectrometry have been employed for IM-MS depending on the physical state of the analyte. Gas phase samples are typically ionized with radioactive ionization, corona discharge ionization and photoionization techniques. Electrospray ionization is a common method for ionizing samples in solution. Solid-phase analytes are ionized with matrix-assisted laser desorption ionization (MALDI) for large mass molecules or laser desorption ionization (LDI) for molecules with smaller masses.

=== Impact on nutrition === The introduction of refrigeration allowed for the hygienic handling and storage of perishables, and as such, promoted output growth, consumption, and the availability of nutrition. The change in our method of food preservation moved us away from salts to a more manageable sodium level. The ability to move and store perishables such as meat and dairy led to a 1.7% increase in dairy consumption and overall protein intake by 1.25% annually in the US after the 1890s. People were not only consuming these perishables because it became easier for they themselves to store them, but because the innovations in refrigerated transportation and storage led to less spoilage and waste, thereby driving the prices of these products down. Refrigeration accounts for at least 5.1% of the increase in adult stature (in the US) through improved nutrition, and when the indirect effects associated with improvements in the quality of nutrients and the reduction in illness is additionally factored in, the overall impact becomes considerably larger. Recent studies have also shown a negative relationship between the number of refrigerators in a household and the rate of gastric cancer mortality.

Solution concentration Drying gas flow Inlet temperature Spraying gas flow Feed rate From the following input parameters comes a series of pathways a particle can take towards its yielded shape and size. Certain parameters like spraying gas flow, feed rate, and the solution concentration heavily influence the yielded particle size, whereas the inlet temperature plays a significant role into the shape of the particle at the end. Particle size has a great correlation with the original size of the solution droplet from the atomizer, so the greatest way to control particle size can be done by heavily saturating the solution and making the initial droplet larger or smaller. Once the initial droplet enters the drying chamber, the droplet can continue to crust formation, or no particle will be formed. From the crust formation, the temperature of the drying process and duration of the particle in the drying process can lead the particle toward a dry shell or a deformed particle. The dry shell can proceed into a solid particle or a shattered particle. The crust formation can also forgo the dry shell or deformed particle if the drying conditions are not correct and undergo an internal bubble nucleation with another series of pathways.

A Border checkpoint is a place where goods or individuals moving across borders are inspected for compliance with border control measures. Access-controlled borders often have a limited number of checkpoints where they can be crossed without legal sanctions. Arrangements or treaties may be established to allow or mandate less-restrained crossings (e.g., the Schengen Agreement). Land border checkpoints (land ports of entry) can be contrasted with the customs and immigration facilities at seaports, international airports, and other ports of entry. Checkpoints generally serve two purposes:

Sources: en.wikipedia.org

Background from the literature

Indoor combustion, such as for cooking or heating, is a major cause of indoor air pollution and causes significant health harms and premature deaths. Hydrocarbon fires cause air pollution. Pollution is caused by both biomass and fossil fuels of various types, but some forms of fuels are more harmful than others. Indoor fire can produce black carbon particles, nitrogen oxides, sulfur oxides, and mercury compounds, among other emissions. Around 3 billion people cook over open fires or on rudimentary cook stoves. Cooking fuels are coal, wood, animal dung, and crop residues. IAQ is a particular concern in low and middle-income countries where such practices are common. Cooking using natural gas (also called fossil gas, methane gas or simply gas) is associated with poorer indoor air quality. Combustion of gas produces nitrogen dioxide and carbon monoxide, and can lead to increased concentrations of nitrogen dioxide throughout the home environment which is linked to respiratory issues and diseases.

Josephine Bunch is a fellow at the National Physical Laboratory. She is Chair of Biomolecular Mass Spectrometry at Imperial College London and the co-director of the National Centre of Excellence in Mass Spectrometry Imaging.

Researchers reported numerous "chemical strains" or chemotypes: lichens identical in appearance yet separable by their metabolites. For instance, MacKenzie (1951) noted that morphologically identical Stereocaulon tomentosum forms differed in chemistry—one containing stictic acid, the other fumarprotocetraric acid. These chemotypes often occupy different regions or microhabitats, and breeding or DNA data have since supported treating them as separate species. Metabolite profiles also informed higher-level classification. In some cases, entire genera were defined or redefined by their chemical profiles. In the Cetraria group, species rich in specific fatty acids were placed in Platismatia, whereas taxa containing orcinol depsidones were transferred to Cetrelia; the shift was consistent with their chemical differences. Chemical data further resolved misclassifications based solely on morphology. For example, species formerly combined in Anaptychia were divided after researchers noted that forms with thick-walled spores and a medulla containing zeorin plus specific depsidones formed a coherent group (Heterodermia), whereas thin-walled, chemically simpler taxa stayed in Anaptychia.

In enzymology, 4-aminobutyrate transaminase (EC 2.6.1.19), also called GABA transaminase or 4-aminobutyrate aminotransferase, or GABA-T, is an enzyme that catalyzes the reversible chemical reaction: GABA + α-ketoglutaric acid ⇌ {\displaystyle \rightleftharpoons } succinate semialdehyde + L-glutamic acid The two substrates of this enzyme are GABA and α-ketoglutaric acid. Its products are succinate semialdehyde and L-glutamic acid. Th enzyme is a transferase, specifically a transaminase, which transfer nitrogenous groups. The systematic name of this enzyme class is 4-aminobutanoate:2-oxoglutarate aminotransferase. This enzyme participates in 5 metabolic pathways: alanine and aspartate metabolism, glutamate metabolism, β-alanine metabolism, propanoate metabolism, and butanoate metabolism. It uses pyridoxal phosphate as a cofactor. This enzyme is found in prokaryotes, plants, fungi, and animals (including humans). Pigs have often been used when studying how this protein may work in humans.

Uranium-235 makes up about 0.72% of natural uranium. Unlike the predominant isotope uranium-238, it is fissile, i.e., it can sustain a fission chain reaction. It is the only fissile isotope that is a primordial nuclide or found in significant quantity in nature. Uranium-235 has a half-life of 704 million years. It was discovered in 1935 by Arthur Jeffrey Dempster. Its fission cross section for slow thermal neutrons is about 584.3±1 barns. For fast neutrons it is on the order of 1 barn. At thermal energy levels, about 5 of 6 neutron absorptions result in fission and 1 of 6 result in neutron capture forming uranium-236. The fission-to-capture ratio improves for faster neutrons.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.

How does TB-500 appear in the literature?

It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

Network